Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
US-2024352036-A1 · Oct 24, 2024 · US
US9518084B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9518084-B2 |
| Application number | US-201113698624-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 25, 2011 |
| Priority date | May 25, 2010 |
| Publication date | Dec 13, 2016 |
| Grant date | Dec 13, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Described is an epitope tag useful in affinity-based applications. The invention further includes fusion proteins, methods for preparing fusion proteins, nucleic acid molecules encoding these fusion proteins and recombinant host cells that contain these nucleic acid molecules. The invention also relates to nanobodies and other affinity ligands specifically recognizing the epitope tag, and uses thereof in affinity-based applications.
Opening claim text (preview).
The invention claimed is: 1. A method for purifying a non-naturally occurring fusion protein comprising (i) an epitope tag consisting of SEQ ID NO:1 and (ii) a target protein, the method comprising: a) applying a solution containing the non-naturally occurring fusion protein to a solid support possessing an immobilized affinity ligand that binds to an epitope tag consisting of SEQ ID NO:1, wherein the solid support is a column or a bead, and wherein the affinity ligand is an antibody, antibody fragment, or single-domain antibody; b) forming a complex between the immobilized affinity ligand and the non-naturally occurring fusion protein; c) removing weakly bound or unbound molecules; and d) eluting bound molecules. 2. The method of claim 1 , wherein the solid support is a bead. 3. A method for immobilizing and/or capturing a non-naturally occurring fusion protein on a solid support, wherein the non-naturally occurring fusion protein comprises (i) an epitope tag consisting of SEQ ID NO:1 and (ii) a target protein, the method comprising: a) applying a solution containing a non-naturally occurring fusion protein to a solid support possessing an immobilized affinity ligand that binds to an epitope tag consisting of SEQ ID NO:1, wherein the solid support is a column or a bead, and wherein the affinity ligand is an antibody, antibody fragment, or single-domain antibody; b) forming a complex between the immobilized affinity ligand and the fusion protein; and c) removing weakly bound or unbound molecules. 4. The method of claim 3 , wherein the solid support is a bead. 5. The method of claim 3 , wherein the solid support is a column. 6. The method of claim 1 , wherein the solid support is a column.
with the first amino acid being acidic · CPC title
Affinity chromatography or related techniques based upon selective absorption processes · CPC title
containing a tag for immunodetection, or an epitope for immunisation · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.